News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alacris Theranostics GmbH Announces Illumina, Inc. (ILMN) CSPro Certification for Next Generation Sequencing


6/11/2013 9:42:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Berlin, Germany, June 11, 2013 - Alacris Theranostics GmbH announced today that it has successfully completed Illumina CSPro(TM) certification for next generation sequencing (NGS); gaining entry to an elite global group of Illumina genomics service providers. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.

Illumina CSPro is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes. "Alacris Theranostics is advancing the field of personalised medicine by developing new approaches for the prediction of drug treatments. To this end the company is applying its proprietary systems biology model, ModCell(TM) for use in drug development projects for Pharma and patient stratification in clinical research projects. For the development of ModCell(TM) high quality NGS data provided for example through the Illumina technology is the basis for precise modelling predictions. Alacris also provides expertise in sequencing, analysis and mathematical modelling within global personalised medicine-oriented projects (for example OncoTrack (www.oncotrack.eu)). Becoming an Illumina CSPro for NGS is valuable confirmation of Alacris Theranostics' excellent management, laboratory and analysis standards, important for both the company and its clients."

"Illumina CSPro recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis," said Karen Possemato, Illumina's Sr. Director of Corporate Marketing. Now that Alacris Theranostics is a global CSPro partner, we are excited to work with them to make it easier for researchers in Germany to access the power of Illumina's genetic analysis technologies."

About Alacris Theranostics

Alacris Theranostics GmbH is a Berlin-based company specialising in the development of new personalised medicine approaches for cancer patient diagnosis, treatment and drug stratification. Using its proprietary virtual patient model ModCell(TM) Alacris can perform personalised prediction of drug treatments, supporting its clients for drug development and in clinical trials by matching patients to therapies and therapies to patients. The Alacris Theranostics team has a strong background in academic cancer research and collaborates closely with oncologists and pharmaceutical companies worldwide. It also possesses extensive expertise in all aspects of NGS, from initial experimental design through to the comprehensive analysis of sequence data, offering this service also for a wide range of applications, including whole genome and targeted sequencing, ChIP-Seq, RNA-Seq and microRNA/small RNA analysis of (clinical) tumor and normal tissue samples.

Contact:

Alacris Theranostics GmbH

Dr. B. Lange

Fabeckstrasse 60-62

D-14195 Berlin

Phone: +49 30 8413-1471

Fax: +49 30 8413-1465

Email: info@alacris.de

Web: www.alacris.de

MC Services AG

Anne Hennecke, Managing Partner

Phone: +49 89 210 228 18

Email: anne.hennecke@mc-services.eu

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES